Arcutis Biotherapeutics Projects Surge In Q4 Revenue Growth

(RTTNews) - Arcutis Biotherapeutics Inc. (ARQT) expects product revenue for the fourth quarter of 2024 to be about $63 million, representing growth of approximately 366% as compared to the fourth quarter of 2023 and approximately 41% as compared to the third quarter of 2024.

Revenue growth in the fourth quarter across the franchise was driven by strong demand for all ZORYVE (roflumilast) indications, while GTN was similar to the prior quarter.

Arcutis noted that it will report complete fourth quarter and full-year 2024 financial results and provide a business update on Tuesday, February 25, 2025 after the U.S. financial markets close.